Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HER-2 Positive Breast Cancer × Doxorubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 130 Lymphoma 91 Lymphoma, Large B-Cell, Diffuse 70 Sarcoma 56 Hodgkin Disease 41 Precursor Cell Lymphoblastic Leukemia-Lymphoma 34 Burkitt Lymphoma 31 Triple Negative Breast Neoplasms 27 Lymphoma, Mantle-Cell 26 Lymphoma, Non-Hodgkin 25 Lymphoma, Follicular 22 Leukemia 22 Neoplasms 19 Neoplasm Metastasis 18 Neuroblastoma 16 Multiple Myeloma 16 Ovarian Neoplasms 15 Carcinoma, Hepatocellular 15 Lymphoma, B-Cell 14 Prostatic Neoplasms 11 Osteosarcoma 11 Liver Neoplasms 11 Urinary Bladder Neoplasms 10 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10 Lymphoma, T-Cell, Peripheral 10 Lymphoma, Large-Cell, Anaplastic 10 Breast Neoplasms, Male 10 Lymphoma, Large-Cell, Immunoblastic 9 Dendritic Cell Sarcoma, Interdigitating 9 Inflammatory Breast Neoplasms 8

Interventions

liposomal doxorubicin 1 Trastuzumab 1 Metformin 1 Doxorubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488564 2025-02-03

met-HEReMYTA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡